Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory follicular lymphoma who have received ≥ 2 prior lines of therapy: Pivotal results from a phase I/II study Meeting Abstract
| Authors: | Budde, E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L.; Wei, M. C.; Yin, S.; Doral, M. Y.; Li, C. C.; Huang, H.; Negricea, R.; Penuel, E.; O'Hear, C.; Bartlett, N. L.; El-Sharkawi, D. |
| Abstract Title: | Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory follicular lymphoma who have received ≥ 2 prior lines of therapy: Pivotal results from a phase I/II study |
| Meeting Title: | 62nd Annual Scientific Meeting of the British Society for Haematology |
| Journal Title: | British Journal of Haematology |
| Volume: | 197 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Apr 3-5 |
| Meeting Location: | Manchester, United Kingdom |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2022-04-01 |
| Start Page: | 18 |
| End Page: | 20 |
| Language: | English |
| ACCESSION: | WOS:000776484300020 |
| PROVIDER: | wos |
| PUBMED: | 35362090 |
| DOI: | 10.1111/bjh.18132 |
| Notes: | Meeting Abstract: BSH22-OR13 -- Hybrid meeting, also held virtually -- Source: Wos |
